Radhashok Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 13-12-2024
- Paid Up Capital ₹ 1.80 M
as on 13-12-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 21.34 Cr
as on 13-12-2024
- Revenue 17.08%
(FY 2024)
- Profit 46.06%
(FY 2024)
- Ebitda 50.66%
(FY 2024)
- Net Worth 29.61%
(FY 2024)
- Total Assets 23.58%
(FY 2024)
About Radhashok Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.80 M.
The company currently has active open charges totaling ₹21.34 Cr.
Anshul Agarwal, Anjul Agarwal, Priyanka Mittal, and Three other members serve as directors at the Company.
- CIN/LLPIN
U74999UP2016PTC082915
- Company No.
082915
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 May 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Agra, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Radhashok Pharmachem?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anshul Agarwal  | Director | 04-May-2016 | Current |
| Anjul Agarwal | Director | 31-Aug-2018 | Current |
| Priyanka Mittal | Director | 10-Jan-2018 | Current |
| Dhanesh Mittal | Director | 07-Jun-2018 | Current |
| Anuradha Agarwal | Director | 22-Jun-2022 | Current |
| Sankalp Mittal | Director | 11-Dec-2023 | Current |
Financial Performance and Corporate Structure Insights of Radhashok Pharmachem.
Radhashok Pharmachem Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 17.08% increase. The company also saw a substantial improvement in profitability, with a 46.06% increase in profit. The company's net worth Soared by an impressive increase of 29.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Radhashok Pharmachem?
In 2024, Radhashok Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 26 Aug 2020 | ₹1.11 M | Open |
Axis Bank Limited Creation Date: 23 Aug 2018 | ₹21.23 Cr | Open |
How Many Employees Work at Radhashok Pharmachem?
Unlock and access historical data on people associated with Radhashok Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Radhashok Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Radhashok Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
